Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.55 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.55 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.55 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.54 |
| ▸ | NMUR1 | Q9HB89 | 1/20 | 0.54 |
| ▸ | REN | P00797 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30248974 | 0.95 | SLC6A2 (0.66) | SLC6A2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30249030 | 0.94 | NTSR2 (0.58) | SLC6A2NTSR2NTSR1SORT1REN | |
| SCHEMBL30446531 | 0.93 | NTSR2 (0.55) | SLC6A2NTSR2NTSR1SORT1REN | |
| SCHEMBL30248936 | 0.92 | SLC6A2 (0.53) | SLC6A2NTSR2NTSR1SORT1NMUR2 | |
| SCHEMBL30249009 | 0.92 | SLC6A2 (0.63) | SLC6A2NTSR2NTSR1SORT1OPRM1 | |
| SCHEMBL30248935 | 0.89 | REN (0.52) | SLC6A2NTSR2NTSR1SORT1NMUR2 | |
| SCHEMBL30249075 | 0.89 | NTSR2 (0.57) | SLC6A2NTSR2NTSR1SORT1REN | |
| SCHEMBL31362642 | 0.89 | SLC6A2 (0.75) | SLC6A2OPRM1OPRD1NMUR2NMUR1 | |
| SCHEMBL30446614 | 0.88 | NTSR2 (0.56) | SLC6A2NTSR2NTSR1SORT1NMUR2 | |
| SCHEMBL30478148 | 0.88 | SLC6A2 (0.59) | SLC6A2NTSR2NTSR1SORT1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | ICHIMARU PHARCOS CO., LTD. (JP) | 2023-06-08 | — | — | US | disclosed |
| EP-4137502-A1 | VIPR2 ANTAGONIST PEPTIDE | Ichimaru Pharcos Co., Ltd. (JP) | 2023-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230174582-A1 | VIPR2 ANTAGONIST PEPTIDE | VIPR2, NPY2R, NPY5R | SLC6A2 1059/4885NTSR2 64/4885NTSR1 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.